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Abstract
Background: We sought to compare frequencies of HFE C282Y and H63D alleles and associated
odds ratios (OR) in 100 consecutive unrelated white adults with malignancy to those in 318
controls.
Methods: Data from patients with more than one malignancy were analyzed according to each
primary malignancy. For the present study, OR ≥2.0 or ≤0.5 was defined to be increased or
decreased, respectively.
Results: There were 110 primary malignancies (52 hematologic neoplasms, 58 carcinomas) in the
100 adult patients. Allele frequencies were similar in patients and controls (C282Y: 0.0850 vs.
0.0896, respectively (OR = 0.9); H63D: 0.1400 vs. 0.1447, respectively (OR = 0.9)). Two patients
had hemochromatosis and C282Y homozygosity. With C282Y, increased OR occurred in non-
Hodgkin lymphoma, myeloproliferative disorders, and adenocarcinoma of prostate (2.0, 2.8, and
3.4, respectively); OR was decreased in myelodysplasia (0.4). With H63D, increased OR occurred
in myeloproliferative disorders and adenocarcinomas of breast and prostate (2.4, 2.0, and 2.0,
respectively); OR was decreased in non-Hodgkin lymphoma and B-chronic lymphocytic leukemia
(0.5 and 0.4, respectively).
Conclusions:  In 100 consecutive adults with malignancy evaluated in a community medical
oncology practice, frequencies of HFE C282Y or H63D were similar to those in the general
population. This suggests that C282Y or H63D is not associated with an overall increase in cancer
risk. However, odds ratios computed in the present study suggest that increased (or decreased)
risk for developing specific types of malignancy may be associated with the inheritance of HFE
C282Y or H63D. Study of more patients with these specific types of malignancies is needed to
determine if trends described herein would remain and yield significant differences.
Background
An increased prevalence of certain types of malignancy
has been reported in putative hemochromatosis heterozy-
gotes characterized by iron phenotype criteria or family
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studies [1-4]. However, discovery of the HFE  gene on
Ch6p and two common hemochromatosis-associated
HFE missense mutations C282Y (exon 4; nt 845G→A)
and H63D (exon 2; nt 187 C→G) [5] permits definition
of hemochromatosis heterozygosity using molecular crite-
ria. Subsequently, other investigators have reported that
the frequency of C282Y in males with childhood acute
lymphoblastic leukemia and in women with lung cancer
is significantly increased [6,7]. The frequency of H63D
was also significantly increased in adults with malignant
gliomas [8]. Further, it has been postulated that increased
susceptibility to malignancy of persons with C282Y could
partly explain age-related reduction in the frequency of
C282Y heterozygotes reported in Swedish people, a pop-
ulation with a high C282Y allele frequency [9]. However,
it is unknown whether the frequencies of C282Y or H63D
are generally increased (or decreased) in persons with
diverse types of malignancy, as suggested by phenotype
and family studies.
There are also reports of the frequencies of C282Y and
H63D in adults with common types of malignancy,
including plasma cell myeloma [10], myelodysplasia [11-
13], acute non-lymphoblastic leukemia [14], and colon or
rectal cancer [10,15], and in women with breast cancer
[10]. In patients with many other types of malignancy,
however, there are no reports of C282Y or H63D associa-
tion. We evaluated the frequencies of C282Y and H63D
and associated odds ratios (OR) for malignancy in 100
unrelated white adults treated in a community medical
oncology and hematology practice in central Alabama
and in control subjects from the same geographic area. We
compared the present results with those in other reports,
and discuss the pertinence of these observations to the
association of common HFE mutations with malignancy
in adults.
Methods
Selection of Study Subjects
The performance of this study was approved by the Insti-
tutional Review Board of Brookwood Medical Center.
One hundred consecutive unrelated white adults (age ≥
18 years) with malignancy who were treated in a commu-
nity medical oncology and hematology practice in central
Alabama in 1996 – 1997 were included. Patients were
referred for surgical adjuvant chemotherapy or manage-
ment of advanced malignancy; the patients were other-
wise unselected. We excluded a) persons whose only
primary malignancy was non-melanoma skin cancer; b)
persons with chemotherapy- or radiation-associated
malignancies; and 3) persons with types of cancer trans-
mitted as simple Mendelian traits. No patient had a diag-
nosis or family history of hemochromatosis at the time of
referral for management of cancer. 318 apparently healthy
white persons from the general population were used as
controls for C282Y and H63D frequencies [16,17]; a sub-
set of 142 controls was used for HFE genotype frequencies
[16].
Clinical and Laboratory Methods
The diagnosis of each primary cancer was established with
histology; flow cytometry, chromosome analysis, in vitro
demonstration of erythropoietin-independent colony
growth, or bcr/abl oncogene analysis were also used, as
appropriate. The presumptive diagnosis of hemochroma-
tosis was based on persistent transferrin saturation (>60%
for men and >55% for women) [16]. Iron overload was
defined as otherwise unexplained elevation of serum fer-
ritin concentration (>300 ng/mL in men, >200 ng/mL in
women), 3+ or 4+ intrahepatocytic iron visualized by
Perls' acid ferrocyanide staining, or hepatic iron index
≥1.9 [18-20]. Testing for C282Y and H63D using genomic
DNA was performed as previously described; absence of
detectable C282Y or H63D was defined as wt (wild type)
[15,16]. Testing for other HFE missense mutations was
not performed because these are uncommon in white per-
sons in central Alabama [17].
Literature Search
A computerized and manual search was performed to
identify reports of case series of persons with malignan-
cies in whom HFE mutation analysis had been performed.
Statistical Considerations
The present data set consisted of observations on 100 per-
sons who collectively had 110 primary malignancies; data
on non-melanoma skin cancer that occurred in the
present patients were not evaluated. Data from persons
with more than one primary malignancy were categorized
for analysis according to each primary malignancy.
Descriptive data are presented as enumerations, percent-
ages, or frequencies. C282Y or H63D frequencies and HFE
genotype frequencies in patients with malignancy were
compared with those in control subjects using chi-square
analysis or Fisher's exact test (when a number in a cell was
<5) [21]. A value of p < 0.05 was defined as significant.
Odds ratios (OR) were computed as previously described
[22]; OR were not calculated in malignancy categories in
which C282Y or H63D were not detected. For the present
study, we defined an OR of ≤0.5 or ≥2.0 to be decreased
or increased, respectively.
Results
General Characteristics of Patients, Malignancies, and 
Control Subjects
In patients with malignancies, there were 50 men and 50
women. The average age at first diagnosis of malignancy
was 64 ± 14 years (range 20 – 96 years). Two patients were
diagnosed to have hemochromatosis associated with
C282Y homozygosity after diagnosis of malignancy.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/6
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There were 110 primary malignancies. Each of ninety-one
patients had one primary malignancy, and nine persons
had two or more primary malignancies. There were 52
hematologic malignancies, including 27 B-cell neoplasms
and 25 cases of myelodysplasia, myeloproliferative disor-
ders, or acute leukemia (Table 1). There were 58 diagnoses
of carcinoma; 37 were adenocarcinomas of the female
breast, adenocarcinomas of the colon or rectum, or non-
small cell carcinomas of the lung (Table 2). Among con-
trols, there were 158 men and 160 women. Their average
age at the time of HFE mutation analysis was 52 ± 15 years
(range 18 – 86 years).
Frequencies of HFE C282Y and H63D Alleles and HFE 
Genotypes
The frequencies of C282Y were 0.0850 in 100 patients
and 0.0896 in 318 controls (p = 0.9565; OR = 0.9). The
frequencies of H63D were 0.1400 in 100 patients and
0.1447 in 318 controls (p = 0.9663; OR = 0.9). In patients
with malignancy, allele frequencies were similar in men
(C282Y 0.9000; H63D 0.14000) and women (C282Y
0.8000; H63D 0.1400). The HFE genotype frequencies in
patients and in control subjects were: C282Y/C282Y:
0.0200, patients and 0.0031 controls (p = 0.2873, OR =
6.5); H63D/H63D 0.0300 patients and 0.0315 controls
(p = 0.7970, OR = 0.9); C282Y/H63D: 0.0500 patients
and 0.0535 controls (p = 0.9029, OR = 0.9); C282Y/wt:
0.0800 patients and 0.1195 controls (p = 0.3589, OR =
0.6); H63D/wt: 0.1700 patients and 0.1730 controls (p =
0.9355, OR = 0.9); and wt/wt: 0.6500 patients and 0.6195
controls (p = 0.6658, OR = 1.1).
Each of ten patients had two detectable HFE mutations
(HFE genotypes C282Y/C282Y, C282Y/H63D, or H63D/
H63D). A man with Burkitt lymphoma and a woman with
adenocarcinoma of the tail of the pancreas had the geno-
type C282Y/C282Y; both had elevated serum transferrin
saturation values and iron overload. A hemochromatosis
phenotype or iron overload was not detected in other
patients. Five patients were C282Y/H63D compound het-
erozygotes (1 patient each with B-cell chronic lym-
phocytic leukemia, adenocarcinoma of the colon, non-
small cell carcinoma of the lung, and adenocarcinoma of
the prostate, and another patient with polycythemia rubra
vera and non-Hodgkin lymphoma). Three patients had
the genotype H63D/H63D (1 patient each with poly-
cythemia rubra vera, myelodysplasia, and adenocarci-
noma of the breast).
Frequencies of HFE C282Y and H63D Alleles and HFE 
Genotypes in Patients with Two or More Malignancies
In the nine patients, C282Y frequency was 0.0555 (p =
0.9355, OR = 0.6) and H63D frequency was 0.1667 (p =
0.9385, OR = 1.2). Their HFE  genotypes were C282Y/
H63D (n = 1), H63D/wt (n = 2), and wt/wt (n = 6).
Frequencies of HFE C282Y and H63D Alleles in Subgroups 
of Malignancies
In 50 patients with hematologic malignancies, the fre-
quency of C282Y was 0.1000 and the frequency of H63D
was 0.1100; these are similar to the corresponding fre-
quencies in control subjects (0.0896 and 0.1447, respec-
tively). A subgroup of 27 patients had B-cell malignancies
(non-Hodgkin lymphoma, chronic lymphocytic leuke-
mia, plasma cell myeloma, or B-cell acute lymphoblastic
leukemia). The frequency of C282Y in the B-cell malig-
nancies subgroup was similar to that in control subjects
(0.1111 vs. 0.0896; p = 0.7396, OR = 1.3). However, the
Table 1: HFE C282Y and H63D Allele Frequencies in 50 Adults with 52 Hematologic Malignancies.*
Classification of Malignancy (no. of cases) † C282Y Odds Ratio (value of p) H63D Odds Ratio (value of p)
B-cell non-Hodgkin lymphoma (12) 0.1667 2.0 (0.3461) 0.0833 0.5 (0.5848)
B-cell chronic lymphocytic leukemia (9) 0.0555 0.6 (0.9355) 0.0555 0.4 (0.4957)
Plasma cell myeloma (6) 0.0833 0.9 (0.7398) 0 -(0.8538)
Myelodysplasia (13) 0.0385 0.4 (0.6331) 0.1923 1.4 (0.6582)
Myeloproliferative disorders (7) 0.2143 2.8 (0.2597) 0.2857 2.4 (0.2755)
Acute Leukemia (5) 0.1000 1.1 (0.6579) 0 -(0.9565)
* Frequencies of C282Y and H63D were compared to those in 318 controls; odds ratios were not calculated in categories in which C282Y or 
H63D alleles were not detected. † B-cell non-Hodgkin lymphoma included high, intermediate, and low histologic grades in two, four, and six cases, 
respectively. B-cell chronic lymphocytic leukemia included one case of hairy cell leukemia. Plasma cell myeloma was IgG-specific in five cases and 
IgA-specific in one case. Myelodysplasia included eleven cases of refractory anemia (nine with ringed sideroblasts), and two cases of refractory 
anemia with excess blasts in transformation. Myeloproliferative disorders included six cases of polycythemia rubra vera and one case of Ph-positive 
chronic myelogenous leukemia. Among the six patients who had polycythemia rubra vera, two were heterozygous for C282Y, one was a compound 
C282Y/H63D heterozygote, one was homozygous for H63D, and two did not have C282Y or H63D. The one patient with Ph-positive chronic 
myelogenous leukemia was heterozygous for H63D. There were three cases of acute non-lymphoblastic leukemia and two cases of acute 
lymphoblastic leukemia (1 T-cell, 1 B-cell). One man had both B-chronic lymphocytic leukemia and plasma cell myeloma, one man had B-chronic 
lymphocytic leukemia and non-small cell carcinoma of the lung, and one man had B-cell non-Hodgkin lymphoma, adenocarcinoma of the rectum, 
and adenocarcinoma of the kidney. One woman had polycythemia rubra vera and non-Hodgkin lymphoma.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/6
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frequency of H63D in this subgroup was lower than that
in controls (0.0556 vs. 0.1447 controls; p = 0.1055, OR =
0.4). 23 patients had myeloid malignancies (myelodys-
plasia, myeloproliferative disorders, or acute non-lym-
phoblastic leukemia). In this subgroup, the frequencies of
C282Y (0.1042; 5/48) (p = 0.8888, OR = 1.2) and H63D
(0.1875; 9/48) (p = 0.5512, OR = 1.4) were similar to the
corresponding frequencies in control subjects. C282Y and
H63D frequencies in individual diagnostic categories are
displayed in Table 1. In the six patients who had poly-
cythemia rubra vera (Table 1), HFE allele frequencies were
0.2500 for C282Y (p = 0.1817, OR = 3.4) and H63D (p =
0.5031, OR = 2.0), respectively.
The frequencies of C282Y and H63D in 54 patients with
carcinomas were 0.0818 and 0.1455, respectively; these
values are similar to the corresponding frequencies in con-
trol subjects. In 18 women with adenocarcinoma of the
breast, the OR associated with C282Y was 0.3, and the OR
associated with H63D was 2.0 (Table 2). In 12 patients
with adenocarcinoma of the colon or rectum, the frequen-
cies of C282Y and H63D were lower than corresponding
values in control subjects, but these differences were not
statistically significant (Table 2). In patients with carcino-
mas of other primary sites, C282Y and H63D frequency
values were similar to respective frequencies in control
subjects (Table 2).
Discussion
The present 100 consecutive adult patients with malig-
nancy were 12 years older than the 318 control subjects,
on average, yet the corresponding frequencies of HFE
C282Y and in the patients and in control subjects were
similar. This is consistent with most studies that demon-
strate that the frequency of the C282Y allele is constant or
nearly so at all ages [23,24]. The corresponding frequen-
cies of HFE C282Y and H63D in the patients and controls
were also similar. Overall, the occurrence of C282Y or
H63D was not associated with an increased (or decreased)
OR for malignancy in the present study. Nonetheless, the
present observations do not exclude the possibility that an
increased (or decreased) risk of developing specific types
of malignancy may be associated with common HFE
mutations.
In the present combined B-cell neoplasm cases, there was
a lower OR in patients with H63D. This may have been
attributable largely to Non-Hodgkin lymphoma cases, in
which we observed an increased OR associated with
C282Y and a decreased OR with H63D. There were no
cases of Hodgkin lymphoma in the present series,
although there was no increase in frequency of C282Y in
121 persons with Hodgkin lymphoma in Wales [25]. In
the present patients with B-chronic lymphocytic leuke-
mia, OR associated with C282Y and H63D were not
increased or decreased; we are unaware of other reports of
HFE allele frequency in B-chronic lymphocytic leukemia.
In the present patients with myeloma, the C282Y fre-
quency was similar to that in control subjects, consistent
with observations in Swedish and Finnish patients with
myeloma [10,26,27].
HFE allele frequencies in the present patients with myelo-
dysplasia were similar to those in control subjects, consist-
ent with previous reports [11-13,27]. In contrast, C282Y
and H63D frequencies were greater in Hungarian patients
with myelodysplasia than in corresponding control sub-
jects in whom HFE mutation frequencies are lower than
Table 2: HFE C282Y and H63D Allele Frequencies in 54 Adults with 58 Carcinomas.*
Histology, Primary Site of Malignancy (no. of cases) † C282Y Odds Ratio (value of p) H63D Odds Ratio (value of p)
Adenocarcinoma of breast (18) 0.0278 0.3 (0.3269) 0.2500 2.0 (0.1386)
Adenocarcinoma of colon or rectum (12) 0.0417 0.4 (0.6445) 0.1250 0.8 (0.9725)
Non-small cell carcinoma of lung (7) 0.1429 1.7 (0.7360) 0 -(0.7631)
Adenocarcinoma of prostate (4) 0.2500 3.4 (0.3230) 0.2500 2.0 (0.6602)
Adenocarcinoma of undetermined primary site (4) 0 -(0.7841) 0 -(0.7267)
Hepatocellular carcinoma (4) 0.1250 1.5 (0.7841) 0.1250 0.8 (0.7267)
Adenocarcinoma of kidney (3) 0 -(0.8695) 0 -(0.6668)
Adenocarcinoma of stomach (3) 0 -(0.8695) 0.1667 1.2 (0.6668)
Miscellaneous (3) 0.3333 ‡ 0.1667 ‡
* Frequencies of C282Y and H63D were compared to those in 318 controls; odds ratios were not calculated in categories in which C282Y or 
H63D alleles were not detected. † All cases of adenocarcinoma of the breast occurred in women. Two women had both adenocarcinoma of the 
breast and B-chronic lymphocytic leukemia; two other women had both adenocarcinoma of the breast and adenocarcinoma of the colon or rectum. 
One man had both B-chronic lymphocytic leukemia and non-small cell carcinoma of the lung, one man had non-small cell carcinoma of the lung and 
adenocarcinoma of the stomach, and a third man had B-cell non-Hodgkin lymphoma, adenocarcinoma of the rectum, and adenocarcinoma of the 
kidney. None of the cases of hepatocellular carcinoma were associated with iron overload. Miscellaneous category includes one case each of 
primary peritoneal adenocarcinoma, adenocarcinoma of the pancreas, and primary cutaneous melanoma. ‡ OR and values of p are not reported for 
this subgroup because it is composed of a heterogeneous group of malignancies.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/6
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those typically observed in western regions of Europe
[28,29]. In the seven present patients with a myeloprolif-
erative disorder (six of whom had polycythemia rubra
vera), C282Y and H63D were associated with increased
OR. In 68 patients in Finland with chronic myelogenous
leukemia, essential thrombocythemia or polycythemia
rubra vera, the frequencies of C282Y and H63D were sim-
ilar to those of population controls [27]. In the present
series, C282Y and H63D frequencies and associated OR
were not significantly different in patients with acute non-
lymphoblastic leukemia than in control subjects, consist-
ent with previous reports [14]. Further, these data are in
agreement with previous reports that post-chemotherapy
iron overload in adults with acute leukemia is not typi-
cally attributable to the inheritance of common HFE alle-
les [30,31].
In Swedish and Australian patients with sporadic colon or
rectal cancer, C282Y and H63D allele frequencies were
similar to those in corresponding control subjects, and the
relative risks for cancer were not increased (or decreased)
[10,15]. The present results are in agreement with these
reports. In contrast, a case-control study of North Carolina
subjects indicates that the OR of the occurrence of colon
cancer in persons with C282Y or H63D was increased
[31]. The frequencies of C282Y and H63D were similar in
Swedish women with breast cancer and in control sub-
jects, and neither allele was associated with increased (or
decreased) risk for breast cancer [10]. In the present study,
however, the occurrence of H63D was associated with an
increased OR. Observations in the small number of lung
cancer cases in the present study suggest that more evalu-
ation of the possible relationship of C282Y and H63D to
this common form of malignancy is needed. In a recent
study, the prevalence of C282Y in women with lung can-
cer was significantly greater than that in men with lung
cancer or in control subjects with head and neck cancer
[7]. In four men with prostate cancer in the present study,
occurrence of C282Y and H63D were associated with
increased OR, but we were unable to identify reports of
other case series of this common malignancy.
In hemochromatosis patients, the prevalence of non-
hepatoma malignancies was higher than normal in some
studies [33-40] but not in others [41-43]. The increased
prevalence of C282Y homozygotes in the present patients
could be attributed to a greater likelihood to develop non-
hepatoma malignancy in persons with hemochromatosis,
or to an ascertainment bias for malignancy and hemo-
chromatosis in patients referred to hematology and med-
ical oncology practices. The prevalence of primary liver
cancer is also increased in putative hemochromatosis
homozygotes identified by phenotype, in
hemochromatosis associated with C282Y homozygosity,
and in persons with C282Y who do not have hepatic cir-
rhosis [39,44,45]. In the present study, however, the two
patients with hemochromatosis and C282Y homozygos-
ity did not have primary liver cancer. The OR associated
with C282Y and H63D in four present patients with pri-
mary liver cancer were not increased or decreased. This is
consistent with previous observations that the frequency
of C282Y and H63D in persons with hepatocellular carci-
noma is similar to that in normal control subjects [46].
There are uncertainties about the conclusions of the
present and related studies. The postulate that there could
be an increased incidence of malignancy in persons with
common HFE mutations is supported by some reports
[6,25,47]. However, some of the present results suggest
that the OR to develop other types of malignancy may be
decreased, although there were few patients in each of sev-
eral diagnosis categories for analysis. We did not study
adults with primary central nervous system malignancies,
primary gynecologic malignancies (e.g., carcinomas of the
endometrium, ovary, or cervix), urothelial malignancies,
soft-part sarcomas, primary bone cancers, or Hodgkin dis-
ease. Some of these malignancies are uncommon, and
some patients are typically not referred to medical oncol-
ogy and hematology practices. None of the present
patients were children. With few exceptions [6,25,47], the
relationship of common HFE mutations to neoplasia in
childhood has not been reported. It is possible that
patients with earlier stages of carcinoma at diagnosis may
have different frequencies of C282Y or H63D than
persons with similar malignancies that were more
advanced at diagnosis. However, this is unlikely in
patients with colon and rectal cancer [15]. There is varia-
bility in the frequency of HFE alleles and HFE genotypes
in persons with hemochromatosis in different subpopula-
tions [48-50]. For example, the reported frequency of
C282Y in population control subjects in studies of malig-
nancy varies from 0.0140 [8] to 0.0850 (present study)
[8,10,15]. The allele frequencies of C282Y and H63D in
the central Alabama whites are relatively great (0.0896
and 0.1447, respectively) [16,17]. Thus, a positive or neg-
ative association of malignancy with HFE genotype in a
population in which the frequency of HFE mutations is
relatively high may be due to chance association with
other genetic or environmental factors. Contrariwise, a
significantly increased relative risk of malignancy may be
more readily demonstrated in populations in which
C282Y or H63D frequencies are lower [8,29]. Thus,
patient age at diagnosis, type of malignancy, expectations
of medical management, stage at diagnosis, and race, eth-
nicity, and population of origin are important potential
sources of variability which must be considered in inter-
preting results of the present and similar reports, and in
designing future studies.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/6
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It is difficult to compare reports of the prevalence of
malignancy in cohorts of putative hemochromatosis het-
erozygotes characterized by phenotype criteria and family
relationships [1-4] to those performed using HFE muta-
tion testing. In epidemiology studies that use data mode-
ling techniques, iron phenotype data are typically
adjusted for common disease-related variables that cause
abnormal serum iron concentrations, transferrin satura-
tion values, or serum ferritin concentrations values, thus
excluding many study subjects from final analysis [2,51].
Phenotypes of hemochromatosis heterozygotes ascer-
tained in HLA-based family studies or in HFE-based stud-
ies are quite variable [38,52]. Thus, using phenotype
criteria to identify C282Y or H63D heterozygotes is often
unreliable. In some studies, presumed hemochromatosis
heterozygotes were ascertained only by self-reported kin-
ship to a putative hemochromatosis homozygote in ques-
tionnaire surveys [53]. In family-based studies in which
HFE mutation or other DNA-based testing is not used,
non-paternity is an additional source of error (1.0 – 1.4%
non-paternity in American Caucasians) [54,55].
The basis for the putative association of common HFE
mutations and malignancy is unknown. Some C282Y het-
erozygotes and many persons with hemochromatosis,
regardless of HFE genotype, have increased body iron con-
tent [1,16,52]. Excess iron could act as a carcinogen due to
oxidative stress [44], activate oncogenes [56], impair cyto-
toxic activity of macrophages [56,57], promote activation,
growth, or proliferation of malignant cells [44,59], or
induce modifications in the immune system [44]. HFE
C282Y may alter iron delivery to tumor cells via transfer-
rin receptor and thus affect their growth rate [60]. Inherit-
ance of the transferrin receptor allele S142G (Ch3) was
associated with an increased OR for development of mye-
loma, colorectal cancer, or breast cancer in adults who
also had HFE C282Y [10]. Common HFE mutations may
be markers linked to other alleles that promote (or
inhibit) neoplasia. For example, Ch6p haplotypes charac-
terized by HLA-A3, B7 are associated with inheritance of
HFE C282Y [16,61]. Similarly, HLA-A3 and B7 have been
associated with increased risks to develop certain types of
malignancy [62-64]. In childhood acute lymphoblastic
leukemia, the frequency of C282Y is significantly
increased in males [6], but the Ch6p alleles HLA-DRB4 (-
DR53) and tumor necrosis factor2-alpha have an even
greater positive association with childhood acute lym-
phoblastic leukemia than does C282Y [24,47]. These
associations and the lack of a gene-dosage effect suggest
that C282Y in childhood acute lymphoblastic leukemia
may be a marker linked to another Ch6p gene involved in
leukemia susceptibility [23].
Conclusions
In 100 consecutive adults with malignancy evaluated in a
community medical oncology practice, frequencies of
HFE C282Y or H63D were similar to those in the general
population. This suggests that C282Y or H63D is not asso-
ciated with an overall increase in cancer risk. However,
odds ratios computed in the present study suggest that
increased (or decreased) risk for developing specific types
of malignancy may be associated with the inheritance of
HFE C282Y or H63D. Study of more patients with these
specific types of malignancies is needed to determine if
trends described herein would remain and yield signifi-
cant differences.
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